1. Home
  2. FOUR vs JAZZ Comparison

FOUR vs JAZZ Comparison

Compare FOUR & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOUR
  • JAZZ
  • Stock Information
  • Founded
  • FOUR 1999
  • JAZZ 2003
  • Country
  • FOUR United States
  • JAZZ Ireland
  • Employees
  • FOUR N/A
  • JAZZ N/A
  • Industry
  • FOUR Business Services
  • JAZZ Biotechnology: Pharmaceutical Preparations
  • Sector
  • FOUR Consumer Discretionary
  • JAZZ Health Care
  • Exchange
  • FOUR Nasdaq
  • JAZZ Nasdaq
  • Market Cap
  • FOUR 6.3B
  • JAZZ 6.7B
  • IPO Year
  • FOUR 2020
  • JAZZ 2007
  • Fundamental
  • Price
  • FOUR $98.01
  • JAZZ $109.39
  • Analyst Decision
  • FOUR Buy
  • JAZZ Strong Buy
  • Analyst Count
  • FOUR 21
  • JAZZ 12
  • Target Price
  • FOUR $113.37
  • JAZZ $183.08
  • AVG Volume (30 Days)
  • FOUR 1.2M
  • JAZZ 662.9K
  • Earning Date
  • FOUR 08-07-2025
  • JAZZ 07-30-2025
  • Dividend Yield
  • FOUR N/A
  • JAZZ N/A
  • EPS Growth
  • FOUR 99.89
  • JAZZ 49.21
  • EPS
  • FOUR 2.82
  • JAZZ 7.51
  • Revenue
  • FOUR $3,471,500,000.00
  • JAZZ $4,064,808,000.00
  • Revenue This Year
  • FOUR $23.49
  • JAZZ $6.05
  • Revenue Next Year
  • FOUR $20.98
  • JAZZ $4.68
  • P/E Ratio
  • FOUR $34.65
  • JAZZ $14.57
  • Revenue Growth
  • FOUR 27.39
  • JAZZ 5.76
  • 52 Week Low
  • FOUR $57.45
  • JAZZ $95.49
  • 52 Week High
  • FOUR $127.50
  • JAZZ $148.06
  • Technical
  • Relative Strength Index (RSI)
  • FOUR 62.03
  • JAZZ 52.16
  • Support Level
  • FOUR $96.36
  • JAZZ $105.26
  • Resistance Level
  • FOUR $100.53
  • JAZZ $111.25
  • Average True Range (ATR)
  • FOUR 2.68
  • JAZZ 2.52
  • MACD
  • FOUR 0.25
  • JAZZ 0.09
  • Stochastic Oscillator
  • FOUR 80.03
  • JAZZ 67.22

About FOUR Shift4 Payments Inc.

Shift4 Payments Inc is provider of integrated payment processing and technology solutions. The company offers software providers a single integration to an end-to-end payments offering, a powerful gateway and a robust suite of technology solutions (including cloud enablement, business intelligence, analytics, and mobile) to enhance the value of their software suites and simplify payment acceptance. The company derives maximum revenue from United States.

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Share on Social Networks: